Extracorporeal cytokine adsorption therapy

Updates of previous evaluations of individual medical procedures by the Austrian Institute for Health Technology Assessment

25

Aug 2020

In July 2020, the Austrian Institute for Health Technology Assessment (AIHTA) published updated evaluations of medical procedures previously assessed. Technologies that were revised are leadless pacemaker for right ventricle pacing and extracorporeal cytokine hemadsorption therapy in patients with sepsis or SIRS. Read more
Extracorporeal cytokine adsorption therapy is currently not recommended for inclusion into the benefit catalogue in Austria for patients with sepsis and SIRS

08

Aug 2017

The Ludwig Boltzmann Institute – Health Technology Assessment (LBI-HTA) has published report with results of systematic literature review of application extracorporeal cytokine adsorption therapy (ECAT) for treatment and prevention of sepsis or systemic inflammatory response syndrome (SIRS). Considered evidence was assessed as insufficient to prove that ECAT is effective and safe procedure in patients with sepsis, septic shock and SIRS. Therefore, ECAT is currently not recommended for inclusion into the benefit catalogue. Read more